Inflammation plays a crucial role in cancer development. In this study, we evaluate the prognostic values of systemic inflammation markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) for the progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
PubMed and the Cochrane Library databases were searched for published studies on the effect of NLR, PLR, and CRP in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
In the meta-analysis, NLR (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.27-3.18; P = .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on progression-free survival, whereas all considered proinflammatory markers had a significant impact on overall survival: NLR (HR, 2.14; 95% CI, 1.67-2.73; P < .001), PLR (HR, 14.67; 95% CI, 11.10-19.57; P < .001), and CRP (HR, 1.96; 95% CI, 1.26-3.05; P = .003).
Inflammation markers such as NLR, PLR, and CRP are predictors of clinical outcome and could provide additional information to individualize treatment.
Clinical genitourinary cancer. 2018 Feb 02 [Epub ahead of print]
Aleksandra Semeniuk-Wojtaś, Arkadiusz Lubas, Rafał Stec, Tomasz Syryło, Stanisław Niemczyk, Cezary Szczylik
Department of Oncology, Military Institute of Medicine, Warsaw, Poland. Electronic address: ., Department of Nephrology, Military Institute of Medicine, Warsaw, Poland., Department of Oncology, Military Institute of Medicine, Warsaw, Poland., Department of Urology, Military Institute of Medicine, Warsaw, Poland., Medical University in Warsaw, Warsaw, Poland.